Prostate cancer remains the most commonly diagnosed cancer in men in the United States, with nearly 300,000 new cases expected by the end of 2024. According to the American Cancer Association, ...

The prognosis of grade group 1 prostate cancer varies widely, with high-risk features increasing the possibility of adverse pathology, biochemical recurrence, and in some cases, death. Gleason grade ...

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment. Biopsy results alone may not fully capture the ...

Data from the SEER and MUSIC registries found a decrease in prostatectomies in those with pathologic grade group 1 prostate cancer. This shift is attributed to evidence supporting active surveillance ...

Grade group 1 and ASAP on prostate biopsy predict future prostate cancer risk and should not be ignored. Prostate biopsy findings of Gleason grade group (GG) 1 or atypical small acinar proliferation ...

New research highlights the challenge of balancing the risks of overdiagnosing and underdiagnosing prostate cancer early enough to intervene and minimize risk of death. Recently, some experts have ...

Findings from a recent study challenge a push to reclassify low grade prostate cancer, Biopsy Gleason Grade Group 1, as “benign.” Anthony D’Amico, MD, PhD, chief of genitourinary radiation oncology at ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

A recent study examined data from more than 10,000 patients with 'Biopsy Gleason Grade Group (GGG) 1,' a diagnosis considered to be the lowest grade cancer. Researchers found that even among patients ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

Researchers have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive ...

Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the ...